SCHEMBL6977670

SCHEMBL6977670

Cc1nc(COc2ccc(C(=O)O)cc2)cs1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
GPBAR1 Q8TDU6 1/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
RAB9A P51151 6/20 0.51
GAA P10253 3/20 0.51
HTT P42858 2/20 0.51
POLB P06746 2/20 0.51
KDM4E B2RXH2 2/20 0.51
NPC1 O15118 5/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
ALOX5 P09917 1/20 0.50
MAPT P10636 1/20 0.49
RXRA P19793 1/20 0.49
RXRB P28702 1/20 0.49
NR4A1 P22736 1/20 0.49
NR4A2 P43354 1/20 0.49
NR4A3 Q92570 1/20 0.49
KDM4A O75164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23488108 0.87 SMN1; SMN2 (0.57) PKML3MBTL1MEN1KMT2ARAB9A
SCHEMBL6968232 0.85 PKM (0.63) PKML3MBTL1MEN1KMT2ARAB9A
Acetic Acid SCHEMBL9385119 0.84 NPC1 (0.65) PKML3MBTL1MEN1KMT2ARAB9A
SCHEMBL3496975 0.83 PKM (0.51) PKML3MBTL1MEN1KMT2ARAB9A
SCHEMBL12090778 0.82 MAPT (0.66) L3MBTL1MEN1KMT2ARAB9AGAA
SCHEMBL7861771 0.82 SMN1; SMN2 (0.71) PKML3MBTL1MEN1KMT2ARAB9A
SCHEMBL6527094 0.80 RAB9A (0.62) PKML3MBTL1GPBAR1RAB9AGAA
SCHEMBL9502821 0.79 MAPT (0.63) L3MBTL1MEN1KMT2ARAB9AGAA
SCHEMBL3997492 0.79 RAB9A (0.63) PKML3MBTL1MEN1KMT2ARAB9A
SCHEMBL14530530 0.78 SMN1; SMN2 (0.52) PKML3MBTL1MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-06-10 US disclosed
CN-1146542-C Benzamide derivatives and their use as cytokine inhibitors 2004-04-21 CN disclosed
EP-1115707-B1 BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2003-11-12 EP disclosed
US-6455520-B1 TUMOR NECROSIS FACTOR AND INTERLEUKIN INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIALLERGENS; BONE DISORDERS ASTRA ZENECA AB (SE) 2002-09-24 US disclosed
CN-1319092-A Benzamide derivatives and their use as cytokine inhibitors ASTRAZENECA AB (SE) 2001-10-24 CN disclosed
EP-1115707-A1 BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-07-18 EP disclosed
WO-2000018738-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 PKM 2276/4885L3MBTL1 4665/4885GPBAR1 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.